Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery.

[1]  Gordon H. Guyatt,et al.  Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk , 2005, Canadian Medical Association Journal.

[2]  Gordon H Guyatt,et al.  How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials , 2005, BMJ : British Medical Journal.

[3]  G. Guyatt,et al.  Are the recommendations to use perioperative β-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? , 2004, Canadian Medical Association Journal.

[4]  G. Jensen,et al.  The Diabetic Postoperative Mortality and Morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgery. , 2004, American heart journal.

[5]  J. Sjögren,et al.  Design of a new multiple-unit controlled-release formulation of metoprolol — Metoprolol CR , 2004, European Journal of Clinical Pharmacology.

[6]  Belinda Young,et al.  Association between cardiac and noncardiac complications in patients undergoing noncardiac surgery: outcomes and effects on length of stay. , 2003, The American journal of medicine.

[7]  P. Grayburn,et al.  Cardiac Events in Patients Undergoing Noncardiac Surgery: Shifting the Paradigm from Noninvasive Risk Stratification to Therapy , 2003, Annals of Internal Medicine.

[8]  E. Antman,et al.  ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluat , 2002, Circulation.

[9]  Michael Schmidt,et al.  Forecasting the impact of a clinical practice guideline for perioperative beta-blockers to reduce cardiovascular morbidity and mortality. , 2002, Archives of internal medicine.

[10]  K Gilbert,et al.  Prospective Evaluation of Cardiac Risk Indices for Patients Undergoing Noncardiac Surgery , 2000, Annals of Internal Medicine.

[11]  Jeroen J. Bax,et al.  The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. , 1999, The New England journal of medicine.

[12]  A S Detsky,et al.  Perioperative Assessment and Management of Risk from Coronary Artery Disease , 1997, Annals of Internal Medicine.

[13]  A. Wallace,et al.  Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. , 1996, The New England journal of medicine.

[14]  T. Riles,et al.  Silent myocardial ischemia monitoring predicts late as well as perioperative cardiac events in patients undergoing vascular surgery. , 1992, Journal of vascular surgery.

[15]  L. Way,et al.  Long-term cardiac prognosis following noncardiac surgery , 1992 .

[16]  R. Bergstrand,et al.  Pharmacokinetic and Biopharmaceutic Aspects of Once Daily Treatment with Metoprolol CR/ZOK: A Review Article , 1990, Journal of clinical pharmacology.

[17]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[18]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[19]  J. Haybittle,et al.  Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.